PDCD1 and cancer: Although immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1), its ligand (PD-L1), or cytotoxic T lymphocyte antigen-4 (CTLA-4) significantly extend overall survival (OS) in patients with diverse types of cancer, it could benefit only a limited subpopulation of patients1.